Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvingtrans Regulatory News (AVG)

Share Price Information for Avingtrans (AVG)

Share Price is delayed by 15 minutes
Get Live Data
625.00    0.00 (0.00%)
Bid:
620.00
Ask:
630.00
Spread: 10.00 (1.613%)
Market Cap: £210.14m
AVG Live PriceLast checked at - London Stock Exchange

Intraday Avingtrans Share Chart

New Contract Win and Framework Agreements

15 Feb 2016 07:00

RNS Number : 9924O
Avingtrans PLC
15 February 2016
 

15 February 2016

Avingtrans Plc

("Avingtrans" or the "Company" or the "Group")

 

New Contract and Framework Agreements for Energy and Medical Division

 

Avingtrans (AIM:AVG), which designs, manufactures and supplies critical components, modules and associated services to the aerospace, energy and medical sectors is pleased to announce that its Energy and Medical division has diversified into the materials technology market, with a contract to provide composite components for airport scanners.

 

Avingtrans has signed an initial contract and three-year framework agreement worth over £3.5 million with Rapiscan, a leading security screening provider based in California. Under the terms of the contract, Avingtrans will provide key components for Rapiscan's new and ground-breaking airport scanner, the RTT110 (Real Time Tomography). The RTT110 is also the first scanner to successfully pass the European Civil Aviation Conference's (ECAC) Standard 3 threat detection test for baggage-borne explosive risks - a standard that will become compulsory for airports around the world by 2020.

 

Additionally, Avingtrans is also pleased to announce that Stainless Metalcraft, also part of the Group's Energy and Medical division, has signed a framework agreement with Bruker BioSpin AG ("Bruker"), a Swiss based market leader in analytical magnetic resonance instruments. Production will initially take place in the UK, before manufacturing transitions to Metalcraft's own established facility in Chengdu, China. Worth £1m per annum, the agreement will see Stainless Metalcraft produce high integrity cryostat components for Bruker's Nuclear Magnetic Resonance systems (NMR). NMR spectroscopy complements other structural and analytical techniques, such as X-ray, crystallography and mass spectrometry and can be used alongside MRI related technology, to provide multidimensional images and spatially resolved information.

 

Austen Adams, Managing Director of Avingtrans' Energy & Medical division, said: "We are delighted to announce these important new work programmes with Rapiscan and Bruker. Both mark an important development in the ongoing diversification of the Energy and Medical division"

 

"We have been working with Rapiscan to develop its RTT110 scanner for a some time now and this supply contract means we can now ramp up production to meet fast-growing demand. Security is a real challenge for airports as passenger numbers increase around the world but, until now, this increase has not been matched by advances in security risk detection technology."

 

"We will work closely with Bruker to develop a fully value-engineered solution for the components for their NMR programmes, ensuring all procedures and processes are firmly established, before transitioning the work to our Chinese site, which will not only bring additional cost efficiency but also bring the manufacturing closer to end customer locations."

 

 

Enquiries:

 

Avingtrans plc

Steve McQuillan, Chief Executive Officer

Stephen King, Chief Financial Officer

 

Tel: 01159 499 020

Numis

David Poutney (Corporate Broking)

Richard Thomas (Corporate Finance and Nominated Adviser)

 

Tel: 0207 260 1000

Newgate (Financial PR)

Adam Lloyd

Ed Treadwell

Tel: 020 7653 9850

 

 

 

About Avingtrans

 

Avingtrans plc is engaged in the provision of highly engineered components, modules and services to the Aerospace, Energy and Medical markets worldwide.

 

The business is made up of two divisions

 

Aerospace, engaged in the manufacture of rigid pipe assemblies, fabrications and prismatic components - both metallic and composite - for the global aerospace market and precision polishing of aircraft components and;

 

Energy and Medical, engaged in the design and manufacture of machined and fabricated pressure and vacuum vessels and process plant and equipment for the power, oil & gas and medical markets. Plus, design and manufacture of fabricated poles and cabinets for roadside safety cameras and rail track signalling.

 

 

About Rapiscan

 

Rapiscan is a global leading security screening provider, manufacturing a variety of products, solutions and services to meet a variety of threat detection needs both for governments and the private sector. Rapiscan is a wholly-owned subsidiary of OSI Systems (NASDAQ:OSIS) and is headquartered in California with additional offices and manufacturing in Finland, India, Malaysia, Singapore, United Kingdom and the United States. Rapiscan specialises in Baggage and Parcel Inspection, Cargo and Vehicle Inspection, Hold Baggage Screening, People Screening, Screening as Service, Total Security Solutions Provider, Radiation Detection and Trace Detection.

 

 

About Brucker BioSpin AG

 

Bruker Corporation is a US based manufacturer of analytical and medical instruments covering NMR, ESR, FT-IR, X-RAY spectroscopy. Brucker BioSpin, the magnetic resonance division of the Corporation, provides a global leading range of magnetic NMR and EPR spectroscopy and preclinical MRI research tools. The Bruker BioSpin Group of companies develop, manufacture and supply technology to research establishments, commercial enterprises and multi-national corporations across countless industries and fields of expertise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQLLFFQLFEBBE
Date   Source Headline
28th Mar 20083:12 pmRNSHolding(s) in Company
10th Mar 20085:30 pmRNSBoard composition
27th Feb 20087:00 amRNSInterim Results
22nd Feb 200810:52 amRNSAppointment of Director
28th Jan 20084:56 pmRNSHolding(s) in Company
25th Jan 20083:16 pmRNSHolding(s) in Company
23rd Jan 20081:01 pmRNSHolding(s) in Company
23rd Jan 20081:00 pmRNSHolding(s) in Company
16th Jan 200811:41 amPRNRe Contract
2nd Jan 20084:23 pmRNSHolding(s) in Company
20th Dec 20075:22 pmRNSDirector/PDMR Shareholding
18th Dec 20072:46 pmRNSTrading Statement
13th Nov 20073:44 pmRNSAdditional Listing
7th Nov 20074:06 pmRNSAnnual Report and Accounts
19th Oct 20073:43 pmPRNAGM Statement
11th Oct 200712:19 pmRNSHolding(s) in Company
13th Sep 20072:55 pmRNSHolding(s) in Company
13th Sep 20077:00 amPRNFinal Results
14th Aug 20072:41 pmRNSAIM Rule 26 Compliance
24th Jul 20071:18 pmRNSDirector Declaration -Amendmt
23rd Jul 20075:24 pmRNSDirector Declaration
7th Jun 200710:59 amPRNInvestment & Trading Update
1st Jun 200710:46 amRNSHolding(s) in Company
31st May 20077:00 amRNSTotal Voting Rights
17th May 20074:58 pmRNSHolding(s) in Company
10th May 20077:01 amRNSDirector/PDMR Shareholding
2nd May 20072:47 pmRNSHolding(s) in Company
2nd May 20077:10 amRNSTrading Statement
1st May 20073:14 pmRNSHolding(s) in Company
20th Apr 200710:56 amRNSHolding(s) in Company
22nd Mar 20079:49 amRNSHolding(s) in Company
22nd Mar 20079:46 amRNSHolding(s) in Company
9th Mar 200712:00 pmRNSHolding(s) in Company
7th Mar 20073:43 pmRNSHolding(s) in Company
21st Feb 20077:00 amPRNInterim Results
6th Feb 20075:20 pmRNSHolding(s) in Company
1st Feb 20077:00 amRNSChange of Adviser
4th Jan 20077:00 amPRNTrading Update
21st Dec 200612:08 pmRNSTotal Voting Rights
21st Dec 200610:14 amRNSDirector/PDMR Shareholding
12th Dec 20061:25 pmRNSHolding(s) in Company
29th Nov 20065:23 pmRNSAdditional Listing
12th Oct 20062:49 pmPRNAGM Statement
5th Oct 20063:31 pmRNSHolding(s) in Company
2nd Oct 20062:00 pmRNSAnnual Report and Accounts
22nd Sep 20069:14 amPRNCompletion of Acquisition
15th Sep 20067:00 amPRNAcquisition & Placing
14th Sep 20065:34 pmRNSDirector/PDMR Shareholding
6th Jul 20067:00 amPRNTrading Statement
20th Jun 20061:58 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.